P441: Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease.ECCO'22Year: 2022
Authors: Moens, A.(1);Verstockt, B.(1);Alsoud, D.(2);Sabino, J.(1);Ferrante, M.(1);Vermeire, S.(1);
(1)University Hospitals Leuven, Department of gastroenterology and Hepatology, Leuven, Belgium;(2)Catholic University Leuven, Department of chronic diseases- metabolism and aging, Leuven, Belgium;
P442: Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative ColitisECCO'22Year: 2022
Authors: Alsoud, D.(1);Compernolle, G.(2);Tops, S.(2);Sabino, J.(1,3);Ferrante, M.(1,3);Thomas, D.(2);De Hertogh, G.(4);Vermeire, S.(1,3);Verstockt , B.(1,3);
(1)KU Leuven, Translational Research in Gastrointestinal Disorders- Department of Chronic Disease- Metabolism and Ageing, Leuven, Belgium;(2)KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies- Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(3)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(4)University Hospitals Leuven, Laboratory of Morphology and Molecular Pathology, Leuven, Belgium;
P444: COVID-19 risk factors, infection course and vaccination among patients with inflammatory bowel disease based on a Hungarian cohortECCO'22Year: 2022
Authors: Farkas, K.(1);Matuz, M.(2);Kata, D.(3);Földesi, I.(3);Resál, T.(1);Bacsur, P.(1);Szántó, K.(1);Kolarovszki-Erdei, D.(1);Rutka, M.(1);Fábián, A.(1);Bor, R.(1);Szepes, Z.(1);Sarlós, P.(4);Miheller, P.(5);Zacháry, A.(6);Molnár, T.(1);
(1)University of Szeged, Department of Medicine- Szent-Györgyi Albert Medical School, Szeged, Hungary;(2)University of Szeged, Department of Clinical Pharmacy- Faculty of Pharmacy- University of Szeged- Szeged- Hungary, Szeged, Hungary;(3)University of Szeged, Department of Laboratory Medicine, Szeged, Hungary;(4)University of Pécs, Gastroenterology Unit- 1st Department of Medicine, Pécs, Hungary;(5)Semmelweis University, Department of Surgery and Interventional Gastroenterology, Budapest, Hungary;(6)Hungarian Association of Crohn's Colitis, Hungarian Association of Crohn's Colitis, Budapest, Hungary;
P445: Is objective disease monitoring strategy tailored to the presence of clinical symptoms, a prospective cohort study from a tertiary IBD center from HungaryECCO'22Year: 2022
Authors: Lontai, L.(1);Gonczi, L.(1);Komlodi, N.(1);Balogh, F.(1);Barkai, L.(1);Ilias, A.(1);LakatosPhD, P.L.(1,2);
(1)Semmelweis University, Department of Medicine and Oncology, Budapest, Hungary;(2)Mcgill University Health Center, IBD Centre, Montréal, Canada;
P446: Long-term Clinical Effectiveness And Stoma Outcome Of Fecal Diversion In Refractory Crohn’s ProctitisECCO'22Year: 2022
Authors: Benammi, S.(1);Perry, W.R.(1);Calini, G.(1);Abdalla, S.(1);Shawki, S.F.(1);Larson, D.W.(1);Mathis, K.L.(1);
(1)Mayo Clinic, Colon and Rectal Surgery, Rochester, United States;
P447: Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn’s diseaseECCO'22Year: 2022
Authors: Alsoud, D.(1);Sabino, J.(1,2);Ferrante, M.(1,2);vermeire, S.(1,2);Verstockt , B.(1,2);
(1)KU Leuven, Translational Research in Gastrointestinal Disorders- Department of Chronic Disease- Metabolism and Ageing, Leuven, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
